Cancer immunotherapy drug discovery outsourcing involves hiring external organizations or research firms to conduct various aspects of research and development for new cancer immunotherapies. This includes tasks such as preclinical testing, clinical trial design, and data analysis. Outsourcing can expedite drug development and reduce costs for pharmaceutical companies. In terms of revenue, the global cancer immunotherapy drug discovery outsourcing market was worth US$ 1.15 Bn in 2022, anticipated to witness CAGR of 9.2% during 2023 – 2031.

Global Cancer Immunotherapy Drug Discovery Outsourcing Market Revenue & Forecast, (US$ Million), 2015 – 2031 

Trends in the Global Cancer Immunotherapy Drug Discovery Outsourcing Market

• Pharmaceutical companies are continuously seeking external partners with specialized knowledge in immunotherapy. This trend is being fueled by the growing complexity of cancer immunotherapies, with companies recognizing the need for outsourced experts who can navigate intricate regulatory pathways, cutting-edge technologies, and personalized medicine approaches. By tapping into external talent, they can stay at the forefront of innovation while efficiently developing novel immunotherapeutic drugs.
• Currently, pharmaceutical companies are prioritizing cost optimization in drug discovery. The high costs associated with in-house research and development has led to a surge in outsourcing activities. By leveraging external research organizations and CROs (Contract Research Organizations), companies can effectively manage their budgets while maintaining a robust pipeline of cancer immunotherapy drugs. This trend enables them to allocate resources strategically and achieve cost-efficiency without compromising on quality or speed in drug development.

The cell-based assays segment has gained popularity in recent years and is anticipated to be the fastest growing segment in the global cancer immunotherapy drug discovery outsourcing market during the forecast period. This remarkable growth can be attributed to the rising demand for accurate and reliable testing methods in cancer immunotherapy development. Cell-based assays play a pivotal role in assessing the efficacy and safety of immunotherapeutic candidates by mimicking the complex interactions within the human body.

These assays offer valuable insights into drug mechanisms, enabling informed decision-making in pharmaceutical development. Their versatility and ability to replicate in vivo conditions make them indispensable in drug discovery. As a result, the cell-based assays segment is witnessing rapid expansion, underlining its critical role in advancing cancer immunotherapy.

Among cancer types, lung cancer had the highest share in the global cancer immunotherapy drug discovery outsourcing market in 2022. The dominance is driven by its staggering prevalence and mortality rates. Lung cancer accounts for a significant portion of global cancer cases, with an estimated 2.2 million new cases annually. Furthermore, it ranks as the leading cause of cancer-related deaths worldwide, responsible for nearly 1.8 million fatalities each year. This high incidence and mortality underline the urgency for effective treatments, spurring substantial investment in immunotherapy drug discovery for lung cancer. The segment’s dominance is a reflection of the pressing need to develop novel therapies to combat this deadly disease.

Asia Pacific is expected to witness the highest growth rate in the cancer immunotherapy drug discovery outsourcing market during the forecast period. This is primarily due to its expanding pharmaceutical and biotechnology industry. With a burgeoning population and increasing cancer incidence rates, Asia Pacific is a vital market for immunotherapy drug discovery. For instance, lung cancer rates are high in countries like China and India, with over 1.3 million cases annually. Additionally, the region offers cost-effective research and development solutions, attracting global pharmaceutical companies to outsource drug discovery activities. Collaborations with leading research institutions and access to a large patient pool further fuel the rapid growth of immunotherapy drug discovery outsourcing in Asia Pacific.

Competitive Landscape

Some of the key companies operating in the cancer immunotherapy drug discovery outsourcing market are

• BPS Bioscience, Inc.
• Celentyx
• Crown Bioscience
• Explicyte Immuno-Oncology
• GenScript
• HD Biosciences Co., Ltd.
• Horizon Discovery Ltd.
• ImmunXperts, a Q² Solutions Company
• Laboratory Corporation of America Holdings
• Personalis, Inc.
• Promega Corporation
• STC Biologics
• Other Industry Participants

Global Cancer Immunotherapy Drug Discovery Outsourcing Market Key Highlights

Global Cancer Immunotherapy Drug Discovery Outsourcing Market

By Drug Type

• Monoclonal Antibodies
• Immunomodulators
• Cancer Vaccines and Oncolytic Viral Therapy
• Others

By Service Type

• Target Identification and Validation
• Lead Screening and Characterization
• Cell-based Assays

By Cancer Type

• Lung
• Breast
• Colorectal
• Melanoma
• Prostate
• Head & Neck
• Ovarian
• Pancreatic

By Region

• North America (U.S., Canada, Mexico, Rest of North America)
• Europe (France, The UK, Spain, Germany, Italy, Nordic Countries (Denmark, Finland, Iceland, Sweden, Norway), Benelux Union (Belgium, The Netherlands, Luxembourg), Rest of Europe)
• Asia Pacific (China, Japan, India, New Zealand, Australia, South Korea, Southeast Asia (Indonesia, Thailand, Malaysia, Singapore, Rest of Southeast Asia), Rest of Asia Pacific)
• Middle East & Africa (Saudi Arabia, UAE, Egypt, Kuwait, South Africa, Rest of Middle East & Africa)
• Latin America (Brazil, Argentina, Rest of Latin America)

Report Layout

Table of Contents

.

.

Note: This ToC is tentative and can be changed according to the research study conducted during the course of report completion

**Exclusive for Multi-User and Enterprise User.

Global Cancer Immunotherapy Drug Discovery Outsourcing Market

By Drug Type

• Monoclonal Antibodies
• Immunomodulators
• Cancer Vaccines and Oncolytic Viral Therapy
• Others

By Service Type

• Target Identification and Validation
• Lead Screening and Characterization
• Cell-based Assays

By Cancer Type

• Lung
• Breast
• Colorectal
• Melanoma
• Prostate
• Head & Neck
• Ovarian
• Pancreatic

By Region

• North America (U.S., Canada, Mexico, Rest of North America)
• Europe (France, The UK, Spain, Germany, Italy, Nordic Countries (Denmark, Finland, Iceland, Sweden, Norway), Benelux Union (Belgium, The Netherlands, Luxembourg), Rest of Europe)
• Asia Pacific (China, Japan, India, New Zealand, Australia, South Korea, Southeast Asia (Indonesia, Thailand, Malaysia, Singapore, Rest of Southeast Asia), Rest of Asia Pacific)
• Middle East & Africa (Saudi Arabia, UAE, Egypt, Kuwait, South Africa, Rest of Middle East & Africa)
• Latin America (Brazil, Argentina, Rest of Latin America)

Note: This ToC is tentative and can be changed according to the research study conducted during the course of report completion

**Exclusive for Multi-User and Enterprise User.

.

The Niche Research approach encompasses both primary and secondary research methods to provide comprehensive insights. While primary research is the cornerstone of our studies, we also incorporate secondary research sources such as company annual reports, premium industry databases, press releases, industry journals, and white papers.

Within our primary research, we actively engage with various industry stakeholders, conducting paid interviews and surveys. Our meticulous analysis extends to every market participant in major countries, allowing us to thoroughly examine their portfolios, calculate market shares, and segment revenues.

Our data collection primarily focuses on individual countries within our research scope, enabling us to estimate regional market sizes. Typically, we employ a bottom-up approach, meticulously tracking trends in different countries. We analyze growth drivers, constraints, technological innovations, and opportunities for each country, ultimately arriving at regional figures.Our process begins by examining the growth prospects of each country. Building upon these insights, we project growth and trends for the entire region. Finally, we utilize our proprietary model to refine estimations and forecasts.

Our data validation standards are integral to ensuring the reliability and accuracy of our research findings. Here’s a breakdown of our data validation processes and the stakeholders we engage with during our primary research:

• Supply Side Analysis: We initiate a supply side analysis by directly contacting market participants, through telephonic interviews and questionnaires containing both open-ended and close-ended questions. We gather information on their portfolios, segment revenues, developments, and growth strategies.
• Demand Side Analysis: To gain insights into adoption trends and consumer preferences, we reach out to target customers and users (non-vendors). This information forms a vital part of the qualitative analysis section of our reports, covering market dynamics, adoption trends, consumer behavior, spending patterns, and other related aspects.
• Consultant Insights: We tap into the expertise of our partner consultants from around the world to obtain their unique viewpoints and perspectives. Their insights contribute to a well-rounded understanding of the markets under investigation.
• In-House Validation: To ensure data accuracy and reliability, we conduct cross-validation of data points and information through our in-house team of consultants and utilize advanced data modeling tools for thorough verification.

The forecasts we provide are based on a comprehensive assessment of various factors, including:

• Market Trends and Past Performance (Last Five Years): We accurately analyze market trends and performance data from preceding five years to identify historical patterns and understand the market’s evolution.
• Historical Performance and Growth of Market Participants: We assess the historical performance and growth trajectories of key market participants. This analysis provides insights into the competitive landscape and individual company strategies.
• Market Determinants Impact Analysis (Next Eight Years): We conduct a rigorous analysis of the factors that are projected to influence the market over the next eight years. This includes assessing both internal and external determinants that can shape market dynamics.
• Drivers and Challenges for the Forecast Period:Identify the factors expected to drive market growth during the forecast period, as well as the challenges that the industry may face. This analysis aids in deriving an accurate growth rate projection.
• New Acquisitions, Collaborations, or Partnerships: We keep a close watch on any new acquisitions, collaborations, or partnerships within the industry. These developments can have a significant impact on market dynamics and competitiveness.
• Macro and Micro Factors Analysis:A thorough examination of both macro-level factors (e.g., economic trends, regulatory changes) and micro-level factors (e.g., technological advancements, consumer preferences) that may influence the market during the forecast period.
• End-User Sentiment Analysis: To understand the market from the end-user perspective, we conduct sentiment analysis. This involves assessing the sentiment, preferences, and feedback of the end-users, which can provide valuable insights into market trends.
• Perspective of Primary Participants: Insights gathered directly from primary research participants play a crucial role in shaping our forecasts. Their perspectives and experiences provide valuable qualitative data.
• Year-on-Year Growth Trend: We utilize a year-on-year growth trend based on historical market growth and expected future trends. This helps in formulating our growth projections, aligning them with the market’s historical performance.

Research process adopted by TNR involves multiple stages, including data collection, validation, quality checks, and presentation. It’s crucial that the data and information we provide add value to your existing market understanding and expertise. We have also established partnerships with business consulting, research, and survey organizations across regions and globally to collaborate on regional analysis and data validation, ensuring the highest level of accuracy and reliability in our reports.